A Closer Look at AirCurve 11 Bilevel Devices

The AirCurve 11 is ResMed’s advanced adaptive servo-ventilation (ASV) device, crucial for treating patients with central sleep apnea, obstructive sleep apnea, mixed apneas, or periodic breathing. It works by simulating the patient’s natural breathing rhythm, to enhance comfort and compliance by providing varying pressure levels during inhalation and exhalation, coinciding with the patient’s normal breathing pattern.

This series integrates a robust combination of features and settings, including integrated cellular communication for secure and automated data transmission to the cloud, accessible via AirView and myAir. The device also features an integrated heated humidifier that can be controlled automatically using the Climate Control feature or manually by the user.

Benefits of the AirCurve 11 Launch

According to ResMed management, the inclusion of coaching features and access to MyAir and AirView for tracking and analyzing nightly sleep data has significantly improved patient compliance. The introduction of digital health applications into the new AirCurve 11 line aims to enhance comfort and support during therapy, aligning with the company’s customer-centric approach to product development.

The Sleep Apnea Treatment Industry and ResMed’s Progress

A report by Grand View Research indicates that the global sleep apnea devices market size was valued at $4.5 billion in 2023 and is expected to grow at a CAGR of 6.2% from 2023 to 2030. The increasing vulnerability of the growing geriatric population to sleep apnea is anticipated to drive the adoption of sleep apnea devices.

ResMed is leveraging traditional healthcare channels and investing in cost-effective social media-driven demand generation campaigns to guide concerned consumers towards the screening, diagnostic, treatment, and management pathways for sleep and breathing issues. Notably, the company is monitoring new patient starts in its physician and provider-based ecosystem, which encompasses over 26 million patient records, and tracking the adoption rates of the myAir app, which continue to be strong.

Moreover, a recently launched in-market trial of a ResMed-developed generative AI product functions as a digital concierge, guiding individuals in seeking information and advice regarding their sleep wellness and potential treatment options.

Price Performance and Zacks Rank of RMD

Over the past year, ResMed’s shares have declined by 14.6%, in contrast to the industry’s growth of 6.6%.

Zacks Rank and Other Key Picks

RMD currently carries a Zacks Rank #3 (Hold). Some other top stocks in the broader medical space include Stryker Corporation SYK, Cencora, Inc. COR and Cardinal Health CAH.

Stryker, with a Zacks Rank #2 (Buy), reported robust fourth-quarter 2023 results, with adjusted EPS and revenues beating estimates. The company also has an estimated earnings growth rate of 11.5% for 2025, surpassing the S&P 500’s 9.9% and demonstrating consistent earnings beats in the preceding quarters.

Cencora, also carrying a Zacks Rank #2, exceeded earnings and revenue estimates for the first quarter of fiscal 2024, demonstrating a strong earnings yield compared to the industry.

Cardinal Health, with a Zacks Rank #2, reported solid second-quarter fiscal 2024 results, with its earnings surpassing estimates and exhibiting a strong long-term estimated earnings growth rate.

This article has been reissued for accuracy, regarding a mistake in the original version released on February 13, 2024.

7 Best Stocks for the Next 30 Days

Our experts have identified 7 elite stocks from a list of 220 Zacks Rank #1 Strong Buys, which they believe are “Most Likely for Early Price Pops.” Since 1988, this elite list has outperformed the market with an average annual gain of +24.0%. Make sure to give these hand-picked 7 stocks your immediate attention.